Article

Milestone for RNAi therapeutics?

A company developing therapeutics using RNA interference (RNAi) today (February 29) linkurl:announced;http://phoenix.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1113937&highlight= positive results of a clinical trial in humans ? marking a first for the much-touted promise of RNAi-based therapies. Alnylam, based in Cambridge, Mass., exposed 88 male volunteers to respiratory syncytial virus, which affects mostly young children and the elderly. Half of the subjects received the

Written byAlla Katsnelson
| 1 min read
Save for Later
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
A company developing therapeutics using RNA interference (RNAi) today (February 29) linkurl:announced;http://phoenix.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1113937&highlight= positive results of a clinical trial in humans ? marking a first for the much-touted promise of RNAi-based therapies. Alnylam, based in Cambridge, Mass., exposed 88 male volunteers to respiratory syncytial virus, which affects mostly young children and the elderly. Half of the subjects received the RNAi treatment, delivered as a nasal spray, which blocked a protein made by the virus, while the other half received a placebo. The upshot: 67% of the treatment group became infected with the virus, while 88% of the placebo group were infected, the linkurl:Wall Street Journal;http://online.wsj.com/article/SB120425827872802381.html?mod=health_home_stories reports; though small, the difference was statistically significant. Researchers have placed high hopes on the potential for RNAi-based therapies, but have linkurl:struggled;http://www.the-scientist.com/blog/display/54268/ with delivery strategies. "With the positive results from GEMINI, we believe that Alnylam has demonstrated the first ever human proof of concept with an RNAi therapeutic," said John Maraganore, the compan"?s CEO, in a press release. The results are not published, but further details of the study will be described this weekend at the International Symposium on Respiratory Viral Infections in Singapore.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free today
Already a member? Login Here

Meet the Author

Share

Related Research Resources

An illustration of PFAS in the bloodstream.

Uncovering the Harmful Effects of PFAS Exposure on the Human Body

Infographic

An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

Infographic

sartorius logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

Article

Wastewater surveillance conceptual visualization of a water droplet containing different microorganism

Elevating Wastewater Epidemiology with Microfluidics

Webinar

Image of a woman with her hands across her stomach. She has a look of discomfort on her face. There is a blown up image of her stomach next to her and it has colorful butterflies and gut bacteria all swarming within the gut.
November 2025, Issue 1

Why Do We Feel Butterflies in the Stomach?

These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Pacific Biosciences logo
Research Roundtable: The Evolving World of Spatial Biology

Research Roundtable: The Evolving World of Spatial Biology

Conceptual cartoon image of gene editing technology

Exploring the State of the Art in Gene Editing Techniques

Bio-Rad
Conceptual image of a doctor holding a brain puzzle, representing Alzheimer's disease diagnosis.

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

fujirebio logo

Products

Product News

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS

The Scientist Placeholder Image

Evosep Unveils Open Innovation Initiative to Expand Standardization in Proteomics

SPT Labtech Logo
OGT logo

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel